We are proud to announce that PhenoPath is now a Quest Diagnostics Company.

PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.

Latest News

  • PhenoPath Conference – Thursday, May 21st, 2020

    Daniel Arber, MD – Topics TBD

    Read More »
  • PhenoPath Conference – Thursday, March 26th, 2020

    Endometrial Cancer, Relevant Issues and Mesenchymal Uterine Neoplasms, Soundtables

    Read More »
  • PhenoPath launches first-ever NGS assay

    Please read the attached letter for additional information.

    Read More »